AbbVie Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Endpoint, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results